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Abstract
Background—Patients with CF treated for pulmonary exacerbations (PEx) may experience 
faster subsequent declines in FEV1. Additionally, incomplete recovery to baseline FEV1 occurs 
frequently following PEx treatment. Whether accelerated declines in FEV1 are preceded by poor 
PEx recovery has not been studied.
Methods—From 2004–2011 CF Foundation Patient Registry data, we randomly selected one 
PEx among patients ≥6 years of age with no organ transplantations, ≥12 months of data before and 
after the PEx, and ≥1 FEV1 recorded within the 6 months before and 3 months after the PEx. We 
defined poor PEx recovery as the best FEV1 in the 3 months after the PEx <90% of the best FEV1 
in the 6 months before the PEx. We calculated mean (95% CI) hazard ratios (HR) of having >5% 
predicted/year FEV1 decline and poor PEx recovery using multi-state Markov models.
Results—From 13,954 PEx, FEV1 declines of >5% predicted/year were more likely to precede 
poor spirometric recovery, HR 1.17 (1.08, 1.26), in Markov models adjusted for age and sex. Non-
Responders were less likely to have a subsequent fast FEV1 decline, HR 0.41 (0.37, 0.46), than 
patients who recovered to >90% of baseline FEV1 following PEx treatment.
Conclusions—Accelerated declines in FEV1 are more likely to precede a PEx with poor 
recovery than to occur in the following year. Preventing or halting declines in FEV1 may also have 
the benefit of preventing PEx episodes.
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1. Introduction
Pulmonary exacerbations (PEx) treated with intravenous (IV) antibiotics in patients with 
cystic fibrosis (CF) are associated with increased mortality, worsening forced expiratory 
volume in one second (FEV1), poorer quality of life, and increased healthcare costs (1–4). 
Epidemiologic studies have shown that patients with CF may have a faster subsequent 
decline in FEV1 after PEx treatment (5, 6). Studies have also shown that patients frequently 
do not recover to near their previous spirometry baseline following a PEx (7–10). The timing 
of these events is important in order to target prevention and treatment strategies: if PEx 
contribute to accelerating FEV1 decline, then preventing or improving outcomes after PExs 
should be a focus. On the other hand, if larger FEV1 declines typically precede PEx 
treatments, then anticipating a PEx by preventing declines in FEV1 should be a focus. We 
hypothesized that patients who experienced poor recovery of FEV1 following treatment with 
IV antibiotics for a PEx would be more likely to have an accelerated subsequent decline in 
FEV1.
2. Methods
Data were obtained from the CF Foundation Patient Registry (CFFPR) between 2004 and 
2011. Written informed consent and assent was obtained for data to be included in the 
CFFPR and the Institutional Review Board of the University of Wisconsin approved the 
study. For this analysis, we included one PEx randomly selected for each patient ≥6 years of 
age if the patient had not had an organ transplantation, there was at least 12 months of data 
available before and after the selected PEx, and there was at least one measurement of FEV1 
recorded within the 6 months before and 3 months after the PEx. Patients were defined as 
Non-Responders if their best FEV1 in the 3 months after the PEx was <90% of the best 
FEV1 in the 6 months before the PEx. We excluded PEx episodes where another PEx 
occurred before the best FEV1 in the 3 months following the PEx. We used linear regression 
to determine the annual change in FEV1 for each individual patient in the 12 months before 
and 12 months after the PEx using all measurements of FEV1 excluding measurements that 
occurred during the PEx. An accelerated decline of FEV1 referred to hereafter as “fast FEV1 
decline” was defined as >5% predicted in the year before or after the PEx; this value 
represents more than double estimates of the average annual decline in FEV1 (2, 11).
PEx recovery and FEV1 declines were modeled using multi-state Markov models (12, 13). 
Multistate Markov models can be used to describe how an individual moves through a series 
of disease states over time. CF lung disease is only observed at arbitrary times (i.e., clinic 
visits, hospitalizations), so that the exact times when the disease state changes are 
unobserved. In Markov models, the next disease state to which the individual moves, or 
“transitions,” and the timing of the change, are governed by a set of transition intensities, or 
probabilities, for each pair of states. These transition intensities represent the instantaneous 
risks of moving from one state to another, and may depend on the time of the process, and 
on individual characteristics such as patient age and sex. Once the Markov model is fitted, 
the ratio of the transition intensities can be used to determine whether one state transition is 
more likely than another. The Markov model assumes all patients begin in the same disease 
state. Once patients progress into a new disease state, they do not transition back.
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For our study, we compared the likelihood of transitioning from a slow to fast FEV1 decline 
and to being a Non-Responder after PEx treatment (Figure 1). Since, if monitored 
continuously, a transition to a fast FEV1 decline and to being a Non-Responder would not 
happen simultaneously, our Markov model did not allow direct transitions from disease state 
1 (neither a fast FEV1 decline nor a Non-Responder) to disease state 4 (fast FEV1 decline 
and Non-Responder). Once patients were classified as having a fast decline in FEV1 or 
being a Non-Responder, they could not transition back to their previous categorization. The 
likelihoods of moving from one disease state to another were modeled using log-linear 
models adjusted for age and sex. Differences in the intercepts of these models represent the 
effects of FEV1 decline on PEx recovery and vice versa. Estimates from the models are 
exponentiated and interpreted as hazard ratios (HR). Analyses were conducted with SAS 
(Version 9.4, SAS Institute Inc, Cary, NC, USA, 2013) and R (version 3.2.1, the R 
Foundation for Statistical Computing, Vienna, Austria, 2015).
3. Results
There were 35,516 patients with 197,085 hospitalizations and/or home courses of IV 
antibiotics recorded in the CFFPR in 2004–2011. Of these, Responder status could be 
determined for 13,954 PExs (1 per patient) that met inclusion/exclusion criteria were 
randomly chosen (Figure E1 online supplement). Cohort characteristics are included in 
Table 1. Comparing the best values of FEV1 before and after the analyzed PEx, 19.8% of 
patients were classified as Non-Responders. Non-Responders were more likely to be adult 
patients, undernourished, on Medicaid/state insurance, have persistent infections with 
Pseudomonas aeruginosa and mucoid P. aeruginosa, have baseline FEV1 <80% predicted, 
and have CF-related diabetes (Table 1).
The mean (SD) best FEV1 recorded in the 6 months prior to the PEx was 70 (26)% 
predicted. Annual declines in FEV1 could be determined for 13,774 patients prior to the PEx 
and 13,953 patients following the PEx, using a mean of 5.3 and 6.0 FEV1 measurements, 
respectively. The median annual decline in FEV1 was −4.3% predicted in the year prior to 
the PEx and −2.6% predicted in the year after the PEx. Forty-eight percent of patients had 
>5% predicted annual decline in FEV1 before the PEx and 40% of patients had >5% 
predicted decline in FEV1 after the PEx. Patients with declines >5% predicted in the year 
prior to the PEx were generally similar to patients with declines ≤5% predicted (see online 
supplement Table E1). At the completion of the study, only 23% of patients were neither 
Non-Responders nor had a fast decline in FEV1.
To determine if being a Non-Responder was more likely to precede or follow a fast FEV1 
decline, we compared the probability of moving from State 3 (fast FEV1 decline only) to 
State 4 (fast FEV1 decline and Non-Responder) to the probability of moving from State 1 
(neither) to State 2 (Non-Responder only) (Figure 1). Patients who were Non-Responders at 
the time of the analyzed PEx were at lower risk of having a subsequent fast decline of FEV1 
than patients who were Responders, HR 0.41 (95% CI 0.37, 0.46).
To determine if having a fast decline in FEV1 was more likely to precede being a Non-
Responder, we compared the probability of moving from State 2 (Non-Responder only) to 
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State 4 (fast FEV1 decline and Non-Responder) to the probability of moving from State 1 
(neither) to State 3 (fast FEV1 decline only). Patients with a fast decline in FEV1 in the year 
prior to the analyzed PEx were at increased risk of being Non-Responders than patients 
without a fast FEV1 decline, HR 1.17 (95% CI 1.08, 1.26).
Results were similar for pediatric and adult patients, and if we used a cut-off of >3% 
predicted/year to define fast FEV1 decline (data not shown). In the year prior to the analyzed 
PEx, 8,069 patients had 0–1 PEx and 5,885 had ≥2 PEx episodes. Patients with 0–1 and ≥2 
PEx episodes in the prior year had similar rates of annual FEV1 decline prior to the analyzed 
PEx. Hazard ratios were similar to the overall cohort, indicating that, regardless of the 
number of PEx in the prior-year, patients who had a fast decline prior to the analyzed PEx 
were at increased risk of being Non-Responders and patients who were Non-Responders at 
the analyzed PEx were at low risk of having a subsequent fast decline in FEV1.
4. Discussion
Epidemiologic studies have demonstrated that pulmonary exacerbations treated with IV 
antibiotics are associated with both acute declines in FEV1 and accelerated subsequent FEV1 
declines (5, 6, 14). Physiologic changes that may occur following a PEx, e.g., changes in the 
inflammatory milieu (15), changes in the microbiota (16), and incomplete spirometric 
recovery, suggest that PEx episodes may lead to further poor outcomes. For example, the 
number of prior PEx is the greatest risk factor for having another PEx treated with IV 
antibiotics (17). In this report, we have attempted to identify whether an accelerated decline 
in FEV1 or poor spirometric recovery following a PEx is more likely to occur first. We 
found that having a fast decline in FEV1 is more likely to precede a PEx. This would suggest 
that efforts to avoid or halt declines in FEV1 will have the added benefit of preventing PEx 
and the many adverse effects associated with PEx. Acute declines in FEV1 are common and 
often do not lead to treatment with IV antibiotics (14). By monitoring and treating these 
acute declines in FEV1clinicians have a significant opportunity to avoid acute PEx and long-
term progression of CF lung disease.
There are limitations to our study. The Markov model assumes that patients are neither Non-
Responders, nor are experiencing fast declines in FEV1 at the start of the study period. 
However, we are not able to verify that that is the case. In part to avoid indication bias, we 
used an annual decline of FEV1 and excluded measurements of FEV1 that occurred during 
the PEx. However, it is possible that acute or subacute decreases in FEV1 that preceded the 
PEx are still captured with our definition of FEV1 decline. Moreover, compartmentalizing 
changes in FEV1 to before, during, and after PExs is an artificial construct necessary for this 
type of analysis. Others have estimated the degree of overall loss of FEV1 that is attributable 
to PEx (5). The mean annual declines in FEV1 (−4.3% predicted prior to the PEx and −2.6% 
predicted after the PEx) are higher than typically reported. This is because in order to use the 
Markov model, it was necessary to calculate the annual FEV1 decline for each individual 
separately. The corresponding mean annual declines in FEV1 for the study cohort were 
−1.1% predicted before and after the PEx, similar to other recent reports that have used data 
from the CFFPR (2, 18, 19). In addition, this is an observational study, so we cannot make 
conclusions about causation. FEV1 measurements are entered into the CFFPR at irregular 
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intervals and may not represent a patient’s best possible values. We excluded PEx if another 
PEx occurred before the best FEV1 in the 3 months following the analyzed PEx was 
recorded, so our results may not apply to patients with short intervals between PEx, who 
may be at higher risk of accelerated FEV1 decline (5).
In conclusion, an accelerated decline of FEV1 is more likely to precede poor spirometric 
recovery from a PEx than to occur in the year following the PEx. Interventional studies 
designed to prevent PEx should consider strategies to prevent or halt declines in FEV1. 
Insights from our observations also support current efforts to monitor FEV1 regularly and 
closely once CF lung disease develops.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Four-state longitudinal model assessing temporal relationships between PEx response and 
FEV1 decline. Patients were assessed before and after a randomly selected PEx and 
classified into one of these four disease states. The relative probability of moving from one 
state to another suggests the temporal relationship between these events. N represents the 
number of patients in each disease state at the end of the study.
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Table 1
Cohort characteristics according to Responder status
Characteristic
Responders
(n=11,192)
N (%) or mean
(SD)
Non-Responders
(n=2,762)
N(%) or mean
(SD)
Total
(n=13,954)
N (%) or mean
(SD)
Female sex 5,654 (50.5) 1,441 (52.2) 7,095 (50.9)
Age (all patients) 20.8 (11.3) 23.1 (11.0) 21.2 (11.2)
Age (pediatric patients) 12.2 (3.5) 12.7 (3.6) 12.3 (3.5)
Adult patients (≥18 years old) 5,674 (50.7) 1,803 (65.3) 7,477 (53.6)
Age (adult patients) 29.1 (9.9) 28.7 (9.4) 29.0 (9.8)
Undernourisheda 1,506 (13.5) 633 (22.9) 2,139 (15.3)
BMI percentile (pediatric patients) 43.3 (26.7) 36.7 (27.6) 42.3 (26.9)
BMI (adult patients) 21.7 (3.6) 20.9 (5.0) 21.5 (4.0)
Pancreatic enzyme replacement therapy 10,471 (93.6) 2,608 (94.4) 13,079 (93.7)
Homozygous F508del 5,478 (48.9) 1,330 (48.1) 6,808 (48.8)
Heterozygous F508del 3,977 (35.5) 983 (35.6) 4,960 (35.6)
Other/Unknown mutations 1,737 (15.5) 449 (16.3) 2,186 (15.7)
Medicaid/state insurance 5,169 (46.2) 1,478 (53.5) 6,647 (47.6)
Persistent P. aeruginosa infectiona 5,540 (49.5) 1,642 (59.6) 7,182 (51.5)
Persistent B. cepacia complex infectiona 296 (2.6) 114 (4.1) 410 (2.9)
Persistent mucoid P. aerginosa infectiona 3,921 (35.0) 1,221 (44.2) 5,142 (36.9)
Persistent MRSA infectiona 2,275 (20.3) 659 (23.9) 2,934 (21.0)
Nontuberculous Mycobacteria 264 (2.4) 73 (2.6) 337 (2.4)
Allergic bronchopulmonary aspergillosis (ABPA) 815 (7.3) 238 (8.6) 1,053 (7.5)
Baseline FEV1
    <40% predicted 1,629 (14.6) 618 (22.4) 2,247 (16.1)
    40–59% predicted 2,092 (18.7) 713 (25.8) 2,805 (20.1)
    60–79% predicted 2,775 (24.8) 617 (22.3) 3,392 (24.3)
    ≥80% predicted 4,691 (41.9) 814 (29.5) 5,505 (39.5)
CF-related diabetes mellitus 2,314 (20.7) 803 (29.1) 3,117 (22.3)
Time between baseline and start of IV antibiotics (weeks) 11.9 (8.3) 14.6 (7.7) 12.4 (8.2)
Change in FEV1 % predicted from baseline to start of IV antibioticsb −13.1 (14.3) −23.9 (16.4) −15.1 (15.3)
PExs treated with IV antibiotics in the previous 12 months 1.6 (1.1) 2.3 (1.5) 1.8 (1.2)
Duration of PEx treatment (days) 15.5 (15.3) 18.2 (22.3) 16.0 (16.9)
a
Persistent infection defined as ≥2 positive culture in the 12 months before the PEx
b
Baseline defined as the best FEV1 % predicted in the 6 months before the PEx among 7,678 patients with FEV1 measured within 3 days of the 
start of IV antibiotics
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